Mode
Text Size
Log in / Sign up
Phase 2 Completed N=57 Randomized Single-blind Treatment

Electroacupuncture for Major Depression

Source: ClinicalTrials.gov NCT00071110 ↗
Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Jan 2010
Primary outcomePrimary: Antidepressant Response, Defined as a Hamilton Depression Rating Scale Score Relative Decrease of 50 % or More and a Final Score < 10 — 11; 11 participants

Summary

This study will compare the safety, efficacy, and tolerability of electroacupuncture (EA) and sham electroacupuncture (SA) for the treatment of major depression.

Outcome Measures

OutcomeResultp-value
PRIMARY
Antidepressant Response, Defined as a Hamilton Depression Rating Scale Score Relative Decrease of 50 % or More and a Final Score < 10
11; 11
SECONDARY
Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Physical Component Score (MOSPCS)
0.54; -1.65 0.32
SECONDARY
Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Mental Component Score (MOSMCS)
6.23; 14.12 0.09
SECONDARY
Change in Functioning and Health-related Quality of Life as Rated by the Medical Outcomes Survey-Version 1 (MOS-36) Bodily Pain Index (MOSBPI)
-1.04; 6.81 0.17

Eligibility Criteria

Inclusion Criteria

  • Meet SCID criteria for a Major Depressive Disorder (Single or Recurrent) with a current major depressive episode of mild or moderate severity
  • Significant symptoms of depression (HRSD > 14)
  • Ability to communicate in English
  • Give informed consent in accordance with local IRB regulations

Exclusion Criteria

  • Personal physician's recommendation against enrollment because the patient is physically unstable or for other reasons
  • Having been treated with acupuncture for any condition
  • History of seizure disorder or significant risk factors for a seizure disorder (e.g., history of brain trauma, recent stroke, or brain tumor)
  • Need to remain on antidepressant or other psychotropic medications
  • Absence of depressive symptoms severe enough (i.e., HRSD < 14) at the baseline assessments
  • Significant cognitive impairment, as assessed by a total score on the MMSE < 25. A recommendation for referral to a neurologist or a psychiatrist will be made to the patient in these cases.
  • Chronic major depression (i.e, duration of 2 years or longer) A recommendation for referral to a psychiatrist will be made in these cases.
  • Major depressive episode severe or severe with psychotic features (as per DSM-IV/SCID) or with acutely suicidality. A recommendation for psychiatric referral will be made in these cases. Bipolar disorder, psychotic features, or a psychotic disorder (specifically: schizophrenia, delusional disorder, or schizoaffective disorder). A recommendation for psychiatric referral will be made in these cases.
  • Met criteria for a diagnosis of alcohol substance abuse or dependence within the past six months. A recommendation for referral to a mental health professional will be made in these cases.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00071110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search